UNITED KINGDOM —Paxman AB has secured its first commercial orders for its proprietary neuropathy management technology within the United Kingdom. A major international healthcare group has committed to deploying four of these systems across private oncology facilities in December 2026. This deployment initiates the commercialisation phase for the company's expansion beyond its established scalp cooling portfolio into broader oncology side effect mitigation.
Chemotherapy-Induced Peripheral Neuropathy (CIPN) represents a frequent and dose-limiting complication across oncology treatments, affecting a significant portion of patients globally and damaging peripheral nerves in extremities. The newly deployed technology utilises specialized cryocompression mechanics designed to lower the incidence and severity of nerve injury, thereby supporting uninterrupted patient regimens.
The commercial rollout follows recent regulatory certification extensions across the United Kingdom and the European Union. Alongside the initial British deployments, pilot programmes are active domestically, with additional European pilot initiatives planned across Germany, France, Spain, Italy, and the Netherlands to evaluate clinical integration.
This commercial milestone highlights growing clinical demand for specialised supportive care technologies that preserve patient quality of life and treatment continuity. Private healthcare providers scaling oncology networks are increasingly adopting preventative solutions to address chronic adverse effects, signaling a broader commercial shift toward comprehensive toxicity management in cancer therapy pathways.
Paxman AB is a medical technology company specializing in oncology side effect management, recognized globally for its scalp cooling systems designed to reduce chemotherapy-induced hair loss. Following its acquisition of Dignitana in 2025, the consolidated enterprise operates an international footprint spanning multiple subsidiaries across Europe and North America.
